Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $147
Benzinga Newsdesk 23 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $147.
Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $147.